AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD: A Real-World Study.

Stool frequency decreased substantially across the study population after three months of AI-guided microbiome modulation.

• Study population consisted of 358 participants with treatment-refractory IBD.
• The intervention lasted three months.
• Stool frequency was reassessed after three months alongside other clinical outcomes.
• The study was a real-world, non-randomized observational design.

Urgency and rectal bleeding resolved in most patients following the three-month intervention.

• Resolution of urgency and rectal bleeding was observed across the 358-participant cohort.
• Over 70% of participants reported a 'much improved' overall condition.
• Clinical outcomes were assessed at three months compared to baseline.
• These improvements occurred in the context of prior failure of multiple therapeutic lines.

Inflammatory biomarkers showed marked normalization, with reductions in hs-CRP and fecal calprotectin observed in over 85% of cases.

• Both high-sensitivity C-reactive protein (hs-CRP) and fecal calprotectin were measured as inflammatory markers.
• Reductions were observed in over 85% of the 358 participants.
• Biomarkers were reassessed after three months of the intervention.
• The authors described the normalization as 'marked.'

Micronutrient deficiencies, particularly iron and zinc, improved following the personalized intervention.

• Baseline micronutrient panels were integrated into the AI platform alongside stool metagenomic sequencing and blood biomarkers.
• Iron and zinc were specifically identified as deficiencies that improved.
• Micronutrient correction was one component of the individualized plans generated by the AI platform.
• Micronutrient status was reassessed at three months.

Beneficial microbial taxa including Faecalibacterium prausnitzii, Bifidobacterium longum, and Akkermansia muciniphila increased significantly after the intervention.

• Baseline stool metagenomic sequencing was used to characterize microbial signatures.
• Microbial signatures were reassessed after three months.
• The three taxa specifically identified as increasing were Faecalibacterium prausnitzii, Bifidobacterium longum, and Akkermansia muciniphila.
• The individualized plans included dietary adjustments, targeted synbiotics, selective antimicrobials, and micronutrient correction to modulate the microbiome.

An AI platform integrated baseline stool metagenomic sequencing, blood biomarkers, micronutrient panels, and clinical data to generate individualized treatment plans for refractory IBD patients.

• The AI-guided program combined dietary adjustments, targeted synbiotics, selective antimicrobials, and micronutrient correction.
• The platform used a multi-omic approach incorporating metagenomic, metabolic, and immune data.
• 358 adults with treatment-refractory IBD participated in the real-world study.
• The program duration was three months.
• Participants had failed multiple prior therapeutic lines before enrollment.